Abstract:Congenital disorders of glycosylation (CDG) are a group of rare monogenic human disorders caused by defects in the genes encoding the proteins that generate, attach, and modify glycans, thus disrupting cellular glycosylation machinery. Over 200 CDG caused by disruptions of 189 different genes are currently known. The multi-system disease manifestations of the CDG disorders highlight the importance of glycosylation across the organ systems. Clinical manifestations of CDG tend to group among genes contributing to the same glycosylation pathways, suggesting shared pathophysiology related to the glycosylation disruptions. However, the underlying glycosylation disruptions and pathophysiologic mechanisms responsible for specific CDG clinical manifestations have been determined for only a few hypoglycosylated proteins. The Frontiers in CDG Consortium (FCDGC) is an international network of clinical sites, laboratories, and patient advocacy groups established in 2019 to improve clinical symptoms, quality of life, and life expectancy for individuals with CDG. FCDGC seeks to answer decades of unresolved questions, address knowledge gaps, develop and validate new biochemical diagnostic techniques and therapeutic biomarkers, and explore novel therapeutic options for CDG. Over the past 5 years, FCDGC has launched a Natural History Study with over 300 CDG patients, discovered novel biomarkers suggesting new mechanisms of disease, and launched clinical trials aiming to restore appropriate glycosylation and targeting newly identified potential mechanisms of disease. Technical advances in glycobiology are making it increasingly possible to comprehensively catalog glycoproteomic data and to probe functional impact of altered glycosylation. My laboratory applies glycoproteomic technologies to samples from human subjects and genetic model systems to identify glycosylation abnormalities and unlock new insights from translational glycobiology. Current findings and accomplishments highlight the ongoing bottlenecks and knowledge gaps at intersections of glycobiology and clinical care requiring further investigation.

International Glycoconjugate Organization (IGO) award for 2015

Editorial: Protein Glycosylation—Advances in Identification, Characterization and Biological Function Elucidation Using Mass Spectrometry

Grand Prix de la Fondation de la Maison de la Chimie—2022 call for nominations

Simultaneous quantification of N- and O-glycans using a solid-phase method

Imaging of protein-specific glycosylation by glycan metabolic tagging and in situ proximity ligation.

Broadening the concept of glycoconjugates: glycoRNA and ubiquitinylated lipopolysaccharide

The Fifth ACGG-DB Meeting Report: Towards an International Glycan Structure Repository

Functional implications of glycans and their curation: insights from the workshop held at the 16th Annual International Biocuration Conference in Padua, Italy

The next Nobel Prize in chemistry or in physiology or medicine

Mass spectrometry-based analysis of IgG glycosylation and its applications

Abstract 4425: GlycoConnect™ immune cell engagers (GC™-ICEs). A non-genetic approach to targeted IL-15 immunotherapy

Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in

Recent advances in immobilization strategies for glycosidases

Sanofi-Cell Research outstanding paper award of 2021

Donor Preactivation‐Based Glycosylation: an Efficient Strategy for Glycan Synthesis

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Uncovering missing glycans and unexpected fragments with pGlycoNovo for site-specific glycosylation analysis across species

Sanofi-<i>Cell Research</i> outstanding paper award of 2020

DrawGlycan-SNFG: a robust tool to render glycans and glycopeptides with fragmentation information

Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024

What comes next in glycobiology